Company profile
CELULARITY INC
NASDAQ:CELUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TANIRALEUCEL | phase1 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02552277 | phase2 | completed | 2015-10-27 | 2017-03-07 | Celularity Incorporated | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy |
| NCT01769755 | phase1 | completed | 2013-03-01 | 2014-11-01 | Celularity Incorporated | A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease |
| NCT02781467 | phase1 | terminated | 2016-07-11 | 2017-12-07 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) |
| NCT02955550 | phase1 | completed | 2017-01-05 | 2018-07-10 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) |
| NCT05218408 | phase1_2 | withdrawn | 2021-09-01 | 2021-10-23 | Celularity Incorporated | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type |
FDA applications (0)
No records yet.